Research ArticleEMERGING INFECTIONS
Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo
- Jose L. Garrido1,2,
- Joseph Prescott3,4,
- Mario Calvo5,
- Felipe Bravo1,2,
- Raymond Alvarez2,
- Alexis Salas6,
- Raul Riquelme7,
- Maria L. Rioseco7,
- Brandi N. Williamson8,
- Elaine Haddock8,
- Heinz Feldmann8 and
- Maria I. Barria1,*
- 1Faculty of Biological Science, Department of Microbiology, Center of Biotechnology, Universidad de Concepción, 4070386 Concepción, Chile.
- 2Ichor Biologics LLC, New York, NY 10065, USA.
- 3Arthropod and Infectious Disease Laboratory, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
- 4Comparative Immunology of Risk Group-4 Viruses, Center for Biological Threats and Special Pathogens, Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany.
- 5Institute of Medicine, Universidad Austral de Chile, Valdivia 5110566, Chile.
- 6Faculty of Biological Science, Department of Pharmacology, Universidad de Concepción, 4070386 Concepción, Chile.
- 7Hospital Regional Dr. Eduardo Schütz, Puerto Montt 5507798, Chile.
- 8Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT 59840, USA.
- ↵*Corresponding author. Email: mbarriac{at}udec.cl
See allHide authors and affiliations
Science Translational Medicine 21 Nov 2018:
Vol. 10, Issue 468, eaat6420
DOI: 10.1126/scitranslmed.aat6420
